undefined(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139

0.0000

+0.0000

--

最高0.0000	最低0.0000	成交量0.00
今开0.0000	昨收0.0000	日振幅0.00%
总市值0.00	流通市值0.00	总股本0.00
成交额0.00	换手率--	流通股本0.00
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","latestPrice":0,"timestamp":0,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatusCode":0,"change":0,"open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"adr":0,"adjPreClose":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"2493781548","title":"美国研究综述-赫希、Paychex、Revvity","url":"https://stock-news.laohu8.com/highlight/detail?id=2493781548","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493781548?lang=zh_cn&edition=full","pubTime":"2024-12-23 15:07","pubTimestamp":1734937640,"startTime":"0","endTime":"0","summary":"美国研究综述-赫希、Paychex、Revvity路透12月23日 - 华尔街证券分析师周一调整了对包括好时、Paychex 和 Revvity 在内的几家美国上市公司的评级和目标价。要闻 * 好时HSY.N：杰富瑞将目标价从155美元下调至150美元 * Paychex Inc PAYX.O：贝尔德将目标价从139美元上调至143美元 * Revvity Inc RVTY.N：杰富瑞将目标价从125美元下调至120美元 * Vertex Pharmaceuticals Inc VRTX.O：丰业银行将目标价从426美元上调至430美元 * Winnebago Industries Inc WGO.N：杰富瑞将目标价从58美元下调至55美元以下是路透周一报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nL4S3NO0D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","HSY","IIPR","LU0114720955.EUR","SJM","RVTY","WGO","LEGN","IE00BZ9MQY76.HKD","HALO","LW","FLO","NBIX","REPL","BK4588","VRTX","LU1035775433.USD","BK4079","LU0054578231.USD","AADI","01548","IE00B19Z9Z06.USD","SYK","VITL","BK1576","PIPR","LEN","LU0128526141.USD","LU2089984988.USD","PAYX","UNIT","LU0109394709.USD","HK0000320264.USD","BGS","BK1141","BK4139","BK4099","GB00B4QBRK32.GBP","LU0234570918.USD","IE00BJT1NW94.SGD","KNF","MGPI","LU0417517546.SGD","CVGW","JLL","IONS","LU1430594728.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0690374961.EUR"],"gpt_icon":0},{"id":"2493208512","title":"恒瑞医药知天命，孙飘扬“人无再少年”","url":"https://stock-news.laohu8.com/highlight/detail?id=2493208512","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493208512?lang=zh_cn&edition=full","pubTime":"2024-12-23 10:13","pubTimestamp":1734919985,"startTime":"0","endTime":"0","summary":"三季报显示，2024年前三季度，恒瑞医药营业收入201.89亿元，同比增长18.67%；归属净利润46.20亿元，同比增长32.98%。恒瑞医药在2023年年报及2024年半年报中均表示期内仿制药收入略有下滑，“仿制药集采对销售仍然造成一定程度的压力”。第10批“国采”中，恒瑞医药共涉及2个品种，拟中标1个。浦银国际研报显示，截至2024年8月22日，恒瑞医药在研创新药主要临床研发管线共有95项。目前，恒瑞医药已经重新提交“双艾”疗法在美上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/247533","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4505","LU0307460666.USD","BK4585","LU2328871848.SGD","BK1583","BK4139","BK4535","BK4548","BGNE","06160","BK4504","BK4526","LU0588546209.SGD","BK1161","LU1969619763.USD","BK4588","BK1588","BK1500"],"gpt_icon":0},{"id":"2493772932","title":"台州博士造药狂飙，剑指200个亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2493772932","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493772932?lang=zh_cn&edition=full","pubTime":"2024-12-23 09:40","pubTimestamp":1734918047,"startTime":"0","endTime":"0","summary":"记者丨韩璐浙商俞德超控制的信达生物，狂飙突进。12月20日，他签发公告宣布，达伯乐?（己二酸他雷替尼胶囊）新药上市申请获批，成为信达第13款商业化产品，将惠及ROS1突变的肺癌患者。“2027年完成20款产品上市。”董事长、CEO俞德超正火力全开，旗下组合格外丰富，从三期临床到上市获批的各类新药，超过30款。1-9月，信达产品收入已超60亿元，增长超5成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202412233275582845.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412233275582845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CDMO","BK4139"],"gpt_icon":0},{"id":"2493327227","title":"南向资金12月20日净买入再鼎医药53.32万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2493327227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493327227?lang=zh_cn&edition=full","pubTime":"2024-12-23 09:30","pubTimestamp":1734917425,"startTime":"0","endTime":"0","summary":"12月20日, 南向资金增持再鼎医药53.32万股，连续3日增持。截止当日收盘，港股通共持有再鼎医药10654.28万股，占流通股9.73%。再鼎医药近5个交易日上涨0.24%，港股通累计增持34.63万股；近20个交易日上涨4.25%，港股通累计增持690.57万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223093330a2034eda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223093330a2034eda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4531","BK4548","09688","BK4526","BK4139","ZLAB"],"gpt_icon":0},{"id":"2493261272","title":"百济神州12月20日获南向资金加仓34.43万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2493261272","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493261272?lang=zh_cn&edition=full","pubTime":"2024-12-23 09:30","pubTimestamp":1734917424,"startTime":"0","endTime":"0","summary":"12月20日, 南向资金增持百济神州34.43万股。截止当日收盘，港股通共持有百济神州7036.97万股，占流通股5.06%。百济神州近5个交易日下跌3.41%，港股通累计增持33.90万股；近20个交易日下跌8.00%，港股通累计增持592.36万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223093311ab8c8b69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223093311ab8c8b69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4504","688235","BK4505","BK4535","BGNE","BK4548","BK4139","06160","BK4526","BK4585","BK4588"],"gpt_icon":0},{"id":"2493272188","title":"海运费1月起全面涨价，背后原因几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2493272188","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493272188?lang=zh_cn&edition=full","pubTime":"2024-12-23 08:59","pubTimestamp":1734915540,"startTime":"0","endTime":"0","summary":"　　海运费1月起全面涨价，背后原因几何？　　近日，多家全球知名海运公司宣布，自2025年1月1日起，将全面上调海运费用。以地中海航运为例，自2025年1月1日起，美西线每40英尺集装箱的运价将提升至6150美元，美东线则涨至7150美元。阳明海运则计划上调综合费率附加费，美西和美东每40英尺集装箱的涨幅均约为2000美元。　　此次海运费涨价的原因复杂多样，涉及市场供需变化、成本上升、外部环境影响及行业竞争策略等多个方面。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/future/fmnews/2024-12-23/doc-ineamaiy9624807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MSC","BK4150","BK4575","BK4139","BK4007","GRI"],"gpt_icon":0},{"id":"2493291421","title":"今天，5000万标箱！再创世界纪录！","url":"https://stock-news.laohu8.com/highlight/detail?id=2493291421","media":"媒体滚动","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493291421?lang=zh_cn&edition=full","pubTime":"2024-12-22 11:28","pubTimestamp":1734838080,"startTime":"0","endTime":"0","summary":"至此，2024年上海港第5000万标准箱装卸成功完成，创下全球港口集装箱运输史上最高纪录，并有望连续第15年居全球首位。而今，上海港再次奋力一跳，跃上5000万标准箱历史新峰，并有望自2010年起连续第15年居世界首位。倘若将这5000万个标准箱依次层层叠放，其高度相当于14600余座珠穆朗玛峰。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2024-12-22/doc-ineaicsv3843609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0048573561.USD","ITOS","LU0122376428.USD","LU0251142724.SGD","BK4139","LU0251131958.USD","LU0368265418.SGD","LU0788109394.HKD","LNG","LU2449327464.USD","IE00B29SXL02.USD","IE00B29SXK94.USD","LU0170899867.USD","BK4144","LU0742534661.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2493260769","title":"肿瘤药竞赛，上了新高度","url":"https://stock-news.laohu8.com/highlight/detail?id=2493260769","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493260769?lang=zh_cn&edition=full","pubTime":"2024-12-22 08:43","pubTimestamp":1734828238,"startTime":"0","endTime":"0","summary":"过去几年，强生在骨髓瘤领域，给市场上了一课。目前，强生富有层次感的交接棒正在形成，相关产品2023年收入也已突破百亿美元大关。这或许也预示了，肿瘤药的竞赛，在不知不觉中已经上了新高度。在这一逻辑下，肿瘤药物的竞争高度不断上行。这也是头部肿瘤药企进行广泛而精准布局的核心。一方面，泽布替尼表现强势，是全球获批适应症最广泛且在CLL新患市场取得领导地位的新一代BTK抑制剂，支","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/247504","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4195","BK4504","BK4588","BK4548","06160","LU1969619763.USD","BK1500","LU0307460666.USD","BK4139","BK4211","BGNE","BK4585","OS","BK1161","BK4526","LU2328871848.SGD","BK1583","BK1588","LU0588546209.SGD","PFS","BK4535","BK4097","BK4505"],"gpt_icon":0},{"id":"2493786474","title":"美国 FDA 拒绝批准 Lexicon Pharma 的糖尿病附加药","url":"https://stock-news.laohu8.com/highlight/detail?id=2493786474","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493786474?lang=zh_cn&edition=full","pubTime":"2024-12-21 05:40","pubTimestamp":1734730827,"startTime":"0","endTime":"0","summary":"美国 FDA 拒绝批准 Lexicon Pharma 的糖尿病附加药路透12月20日 - 美国食品和药物管理局拒绝批准Lexicon Pharmaceuticals公司的LXRX.O治疗1型糖尿病和慢性肾病的附加药物，该公司周五表示。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL4T3NL1BJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXRX"],"gpt_icon":0},{"id":"2493474458","title":"Sarepta 赢得日本新药公司 1.152 亿美元的美国药品专利判决","url":"https://stock-news.laohu8.com/highlight/detail?id=2493474458","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493474458?lang=zh_cn&edition=full","pubTime":"2024-12-21 05:39","pubTimestamp":1734730776,"startTime":"0","endTime":"0","summary":"陪审团还驳回了信谊公司提出的竞争性专利索赔，该公司指控 Sarepta 侵犯了其 DMD 药物 Viltepso 的专利权。陪审团周四裁定，Shinyaku公司的专利 ，该专利无效。Sarepta公司在一份声明中感谢 。2021 年，Shinyaku 在特拉华州联邦法院起诉 Sarepta，指控 Vyondys 53 侵犯了其专利，并要求宣布 Viltepso 没有侵犯 Sarepta 的专利。总部位于马萨诸塞州剑桥市的 Sarepta 公司于 2022 年反诉信乐公司侵权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL4T3NL1BG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","BK4139","IE0002141913.USD","IE00B2B36J28.USD","SRPT","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2493047299","title":"Nanobiotix盘中异动 股价大跌5.49%报3.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493047299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493047299?lang=zh_cn&edition=full","pubTime":"2024-12-21 05:00","pubTimestamp":1734728422,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日05时00分，Nanobiotix股票出现波动，股价快速下跌5.49%。截至发稿，该股报3.10美元/股，成交量5.166万股，换手率0.11%，振幅7.93%。Nanobiotix股票所在的生物技术行业中，整体涨幅为0.05%。Nanobiotix公司简介：Nanobiotix SA 是一家临床阶段的生物技术公司，它有一个运营部门，专注于开发使用其专有纳米技术的产品候选物，以提高放疗的有效性，从而转变癌症治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221050022ab8800d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221050022ab8800d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NBTX"],"gpt_icon":0},{"id":"2493166474","title":"Mdxhealth Sa盘中异动 股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493166474","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493166474?lang=zh_cn&edition=full","pubTime":"2024-12-21 05:00","pubTimestamp":1734728415,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日05时00分，Mdxhealth Sa股票出现波动，股价大幅拉升5.09%。截至发稿，该股报2.27美元/股，成交量9.2933万股，换手率0.19%，振幅10.19%。Mdxhealth Sa股票所在的生命科学行业中，整体涨幅为1.52%。Mdxhealth Sa公司简介：MDxHealth SA 是一家跨国医疗保健公司，提供可操作的分子诊断信息以个性化癌症的诊断和治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221050016984d00c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221050016984d00c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","MDXH"],"gpt_icon":0},{"id":"2493983474","title":"美国OTC市场Finch Therapeutics Group, Inc.盘中异动 临近收盘股价大涨5.77%报11.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493983474","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493983474?lang=zh_cn&edition=full","pubTime":"2024-12-21 04:59","pubTimestamp":1734728357,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日04时59分，美国OTC市场Finch Therapeutics Group, Inc.股票出现波动，股价大幅拉升5.77%。截至发稿，该股报11.00美元/股，成交量357股，换手率0.02%，振幅3.85%。美国OTC市场Finch Therapeutics Group, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。美国OTC市场Finch Therapeutics Group, Inc.公司简介：Finch Therapeutics Group Inc是一家微生物组技术公司，拥有知识产权和微生物组资产组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045918984d00c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045918984d00c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FNCH","BK4139","LENZ"],"gpt_icon":0},{"id":"2493479083","title":"Verastem, Inc.盘中异动 临近收盘急速下跌5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493479083","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493479083?lang=zh_cn&edition=full","pubTime":"2024-12-21 04:58","pubTimestamp":1734728331,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日04时58分，Verastem, Inc.股票出现异动，股价快速下挫5.29%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。消息层面，截至04时58分，《瑞穗银行：维持Verastem评级》资讯为影响Verastem, Inc.的重要信息。该信息摘要如下：瑞穗银行：维持verastem评级，由优于大市调整至优于大市评级,目标价由7.00美元调整至9.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122104585295eaa0fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122104585295eaa0fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VSTM","BK4139"],"gpt_icon":0},{"id":"2493716904","title":"Benitec Biopharma Inc.盘中异动 临近收盘股价大跌5.51%报11.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493716904","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493716904?lang=zh_cn&edition=full","pubTime":"2024-12-21 04:55","pubTimestamp":1734728136,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日04时55分，Benitec Biopharma Inc.股票出现异动，股价大幅下跌5.51%。截至发稿，该股报11.50美元/股，成交量8.4522万股，换手率0.36%，振幅6.16%。Benitec Biopharma Inc.股票所在的生物技术行业中，整体涨幅为0.15%。Benitec Biopharma Inc.公司简介：Benitec Biopharma Inc 是一家临床阶段的生物技术公司，专注于新型基因药物的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045536a1fec355&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045536a1fec355&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BNTC","BK4139"],"gpt_icon":0},{"id":"2493479299","title":"Lyra Therapeutics, Inc.盘中异动 急速上涨6.47%报0.181美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493479299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493479299?lang=zh_cn&edition=full","pubTime":"2024-12-21 04:55","pubTimestamp":1734728130,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日04时55分，Lyra Therapeutics, Inc.股票出现波动，股价快速上涨6.47%。Lyra Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.15%。Lyra Therapeutics, Inc.公司简介：Lyra Therapeutics Inc 是一家临床阶段的治疗公司，专注于新型综合药物和给药解决方案的开发和商业化，用于耳鼻喉疾病患者的局部治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045531ab87ff03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045531ab87ff03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","LYRA"],"gpt_icon":0},{"id":"2493479669","title":"美国 FDA 批准 Vertex 制药公司的囊性纤维化三联疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2493479669","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493479669?lang=zh_cn&edition=full","pubTime":"2024-12-21 04:51","pubTimestamp":1734727875,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透12月20日 - Vertex制药公司周五表示，美国食品和药物管理局已经批准了该公司治疗一种罕见的渐进性遗传疾病的下一代疗法  ，从而扩大了该公司在囊性纤维化市场的主导地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2462157665.USD","LU2236285917.USD","LU0058720904.USD","VRTX","BK4533","IE0009355771.USD","LU0256863811.USD","IE00B19Z9P08.USD","BK4567","BK4585","LU0079474960.USD","IE00BFTCPJ56.SGD","LU0417517546.SGD","LU2237438978.USD","LU0823416689.USD","LU1585245621.USD","VERX","BK4532","IE0002141913.USD","LU1093756168.USD","LU2362541513.USD","IE00B4R5TH58.HKD","LU0109394709.USD","LU1035775433.USD","IE00B19Z3581.USD","IE00B19Z9Z06.USD","LU2324357040.USD","BK4588","BK4023","IE00BJT1NW94.SGD","LU0061475181.USD","IE0002270589.USD","LU1430594728.SGD","LU2456880835.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0234570918.USD","LU0566484027.USD","LU1069344957.HKD","LU2417539215.USD","LU2362540622.SGD","LU0889565916.HKD","LU1559883803.SGD","LU1093756325.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU2362541273.HKD","IE00BZ9MQY76.HKD","LU0320765992.SGD","BK4139"],"gpt_icon":0},{"id":"2493792984","title":"Inhibrx Biosciences, Inc.盘中异动 临近收盘股价大涨5.33%报14.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493792984","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493792984?lang=zh_cn&edition=full","pubTime":"2024-12-21 04:50","pubTimestamp":1734727850,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日04时50分，Inhibrx Biosciences, Inc.股票出现异动，股价大幅拉升5.33%。截至发稿，该股报14.62美元/股，成交量7.4015万股，换手率0.51%，振幅7.64%。Inhibrx Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Inhibrx Biosciences, Inc.公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045050a1fec1dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045050a1fec1dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","INBX"],"gpt_icon":0},{"id":"2493721534","title":"Sera Prognostics, Inc.盘中异动 临近收盘大幅拉升7.01%报8.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493721534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493721534?lang=zh_cn&edition=full","pubTime":"2024-12-21 04:50","pubTimestamp":1734727832,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日04时50分，Sera Prognostics, Inc.股票出现波动，股价快速拉升7.01%。Sera Prognostics, Inc.股票所在的医疗器械行业中，整体涨幅为1.41%。其相关个股中，Helius Medical Technologies, Inc.、Baird Medical Investment Hldgs Ltd C/Wts 01/10/2029 、Aethlon Medical, Inc.涨幅较大，Helius Medical Technologies, Inc.、Aethlon Medical, Inc.、Bone Biologics Corp较为活跃，换手率分别为3213.76%、508.18%、31.45%，振幅较大的相关个股有Helius Medical Technologies, Inc.、Aethlon Medical, Inc.、Pavmed Inc C/Wts 30/04/2025 Class Z，振幅分别为155.81%、80.64%、63.33%。Sera Prognostics, Inc.公司简介：Sera Prognostics Inc 是一家健康诊断公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045032984d00aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045032984d00aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SERA","BK4139","BK4539"],"gpt_icon":0},{"id":"2493479420","title":"Elutia, Inc.盘中异动 急速拉升6.80%报3.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493479420","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493479420?lang=zh_cn&edition=full","pubTime":"2024-12-21 04:50","pubTimestamp":1734727814,"startTime":"0","endTime":"0","summary":"北京时间2024年12月21日04时50分，Elutia, Inc.股票出现波动，股价急速拉升6.80%。截至发稿，该股报3.77美元/股，成交量1.9693万股，换手率0.06%，振幅6.32%。Elutia, Inc.股票所在的医疗器械行业中，整体涨幅为1.41%。Elutia, Inc.公司简介：Elutia Inc 前身为 Aziyo Biologics Inc，是一家商业阶段的再生医学公司，专注于创造下一代差异化产品并改善接受外科手术的患者的结果，并重点关注接受植入式医疗设备的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045014a1fec1ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241221045014a1fec1ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELUT","BK4139"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"undefined(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供undefined(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":",BK4139,股票,股票老虎,股票老虎国际,行情,股票行情,股价,股市,股票价格,股票交易,股票购买,股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"undefined(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供undefined(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}